Evaluation of Antibacterial Efficacy of Photo-activated Riboflavin Using Ultraviolet Light (UVA)

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2009 Nov 19

PMID 19921518

Citations 31

Authors

Karim Makdoumi

Anders Backman

Jes Mortensen

Sven Crafoord

Affiliations

Soon will be listed here.

Abstract

Background: To evaluate the antibacterial efficacy of photo-activated riboflavin using Ultraviolet A (UVA) on three bacterial strains commonly detected in keratitis.

Methods: Three bacterial strains (Staphylococcus epidermidis, Staphylococcus aureus and Pseudomonas aeruginosa) were cultured on blood/hematin-agar plates and dispersed in PBS. Dispersion was done of 10 microl of bacterial stock-solutions in 90 microl of RPMI, where different riboflavin molarities had been added, to achieve a bacterial concentration of 1-4 x 10 (4)/ml. Riboflavin end molarities before illumination were 0, 100, 200, 300 and 400 microM. Each solution had a negative control. The solutions were illuminated with UVA (365 nm) for 30 minutes (5.4 J/cm(2)) and then continued for a total time of 60 minutes (10.8 J/cm(2)). A count of CFU was conducted after incubation and results compared.

Results: In all tested strains, a slight decrease of bacteria was seen when exposed to UV for 30 minutes. A doubling of the UV dose showed a marked decrease of bacterial count in all bacteria tested. The combination of UV and riboflavin showed a more extensive reduction of CFU, confirming an interaction effect between UV and riboflavin.

Conclusion: Riboflavin photo-activation using UVA (365 nm) can achieve an extensive eradication of bacteria, and the combination is more potent in reducing bacterial number than UV alone.

Citing Articles

Photoactivated Chromophore for Keratitis-Corneal Cross-linking (PACK-CXL)-A Scoping Review Based on Preclinical Studies.

Kowalska M, Pot S, Hartnack S Transl Vis Sci Technol. 2024; 13(7):14.

PMID: 39023444 PMC: 11262473. DOI: 10.1167/tvst.13.7.14.

Collagen cross-linking beyond corneal ectasia: A comprehensive review.

Osipyan G, Khraistin H, Jourieh M Indian J Ophthalmol. 2024; 72(Suppl 2):S191-S202.

PMID: 38271415 PMC: 11624635. DOI: 10.4103/IJO.IJO_1507_23.

antimicrobial efficacy of riboflavin, ultraviolet-A radiation, and combined riboflavin/ultraviolet-A radiation on ocular pathogens.

Sharma A, Sharma R, Chander J, Nirankari V Taiwan J Ophthalmol. 2023; 13(1):21-27.

PMID: 37252159 PMC: 10220446. DOI: 10.4103/tjo.tjo_28_21.

How Modifications of Corneal Cross-Linking Protocols Influence Corneal Resistance to Enzymatic Digestion and Treatment Depth.

Kowalska M, Mischi E, Stoma S, Norrelykke S, Hartnack S, Pot S Transl Vis Sci Technol. 2023; 12(5):18.

PMID: 37191620 PMC: 10198285. DOI: 10.1167/tvst.12.5.18.

The Antibacterial Efficacy of High-Fluence PACK Cross-Linking Can Be Accelerated.

Lu N, Koliwer-Brandl H, Gilardoni F, Hafezi N, Knyazer B, Achiron A Transl Vis Sci Technol. 2023; 12(2):12.

PMID: 36757342 PMC: 9924428. DOI: 10.1167/tvst.12.2.12.

References

Picker S, Steisel A, Gathof B . Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion. 2008; 48(8):1685-92. DOI: 10.1111/j.1537-2995.2008.01778.x. View

McGhee C, Niederer R . Resisting susceptibility: bacterial keratitis and generations of antibiotics. Clin Exp Ophthalmol. 2006; 34(1):3-5. DOI: 10.1111/j.1442-9071.2006.01164.x. View

Goodrich R, Edrich R, Li J, Seghatchian J . The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci. 2006; 35(1):5-17. DOI: 10.1016/j.transci.2006.01.007. View

Ruane P, Edrich R, Gampp D, Keil S, Leonard R, Goodrich R . Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004; 44(6):877-85. DOI: 10.1111/j.1537-2995.2004.03355.x. View

ONeill A . New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria. Expert Opin Investig Drugs. 2008; 17(3):297-302. DOI: 10.1517/13543784.17.3.297. View

McGowan Jr J . Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med. 2006; 119(6 Suppl 1):S29-36. DOI: 10.1016/j.amjmed.2006.03.014. View

Reddy H, Dayan A, Cavagnaro J, Gad S, Li J, Goodrich R . Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008; 22(2):133-53. DOI: 10.1016/j.tmrv.2007.12.003. View

Wollensak G . Crosslinking treatment of progressive keratoconus: new hope. Curr Opin Ophthalmol. 2006; 17(4):356-60. DOI: 10.1097/01.icu.0000233954.86723.25. View

Cardo L, Rentas F, Ketchum L, Salata J, Harman R, Melvin W . Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang. 2006; 90(2):85-91. DOI: 10.1111/j.1423-0410.2005.00736.x. View

10.

Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat L . Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008; 34(5):796-801. DOI: 10.1016/j.jcrs.2007.12.039. View

11.

Schnitzler E, Sporl E, Seiler T . [Irradiation of cornea with ultraviolet light and riboflavin administration as a new treatment for erosive corneal processes, preliminary results in four patients]. Klin Monbl Augenheilkd. 2000; 217(3):190-3. DOI: 10.1055/s-2000-10344. View

12.

Moshirfar M, Meyer J, Espandar L . Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2007; 33(11):1978-81. DOI: 10.1016/j.jcrs.2007.07.019. View

13.

Wollensak G, Spoerl E, Seiler T . Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003; 135(5):620-7. DOI: 10.1016/s0002-9394(02)02220-1. View

14.

Kanellopoulos A, Binder P . Collagen cross-linking (CCL) with sequential topography-guided PRK: a temporizing alternative for keratoconus to penetrating keratoplasty. Cornea. 2007; 26(7):891-5. DOI: 10.1097/ICO.0b013e318074e424. View

15.

Tsugita A, Okada Y, Uehara K . Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta. 1965; 103(2):360-3. DOI: 10.1016/0005-2787(65)90182-6. View

16.

Coskunseven E, Jankov 2nd M, Hafezi F . Contralateral eye study of corneal collagen cross-linking with riboflavin and UVA irradiation in patients with keratoconus. J Refract Surg. 2009; 25(4):371-6. DOI: 10.3928/1081597X-20090401-02. View

17.

Wittig-Silva C, Whiting M, Lamoureux E, Lindsay R, Sullivan L, Snibson G . A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008; 24(7):S720-5. DOI: 10.3928/1081597X-20080901-15. View

18.

Betanzos-Cabrera G, Juarez-Verdayes M, Gonzalez-Gonzalez G, Cancino-Diaz M, Cancino-Diaz J . Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis. Ophthalmic Res. 2009; 42(1):43-8. DOI: 10.1159/000219684. View

19.

Kumar V, Lockerbie O, Keil S, Ruane P, Platz M, Martin C . Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004; 80:15-21. DOI: 10.1562/2003-12-23-RA-036.1. View

20.

de la Cruz J, Behlau I, Pineda R . Atypical mycobacteria keratitis after laser in situ keratomileusis unresponsive to fourth-generation fluoroquinolone therapy. J Cataract Refract Surg. 2007; 33(7):1318-21. DOI: 10.1016/j.jcrs.2007.03.035. View